The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...
The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback